Ignite Creation Date:
2024-07-17 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06480552
Status:
RECRUITING
Last Update Posted:
2024-06-28
First Post:
2024-06-10
Brief Title:
An Open-label Dose EscalationExpansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Sponsor:
Teva Branded Pharmaceutical Products RD Inc
Organization:
Teva Branded Pharmaceutical Products RD Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-07-24
Start Date Type:
ESTIMATED
Primary Completion Date:
2029-05-26
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-02-25
Completion Date Type:
ESTIMATED
First Submit Date:
2024-06-10
First Submit QC Date:
None
Study First Post Date:
2024-06-28
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-09-24
Last Update Post Date:
2024-06-28
Last Update Post Date Type:
ACTUAL